Dexmedetomidine for Adult Patients Undergoing Electroconvulsive Therapy: A Systematic Review and Meta-Analysis

Area of Science:

• Anesthesiology
• Cardiology
• Neurology

Background:

• Electroconvulsive therapy (ECT) can cause significant cardiovascular risks due to a pronounced sympathetic surge.
• Dexmedetomidine, an alpha2-adrenergic agonist, is investigated for its potential to mitigate this response.
• Optimal clinical impact and dosing of dexmedetomidine in ECT remain unclear.

Purpose of the Study:

• To systematically review and meta-analyze randomized controlled trials on dexmedetomidine's use before ECT anesthesia.
• To evaluate its effect on heart rate (HR) and mean arterial pressure (MAP).
• To assess impacts on seizure duration, recovery, and adverse events.

Main Methods:

• Systematic review and meta-analysis of 20 double-blind randomized controlled trials.
• Included 1526 adult participants undergoing ECT.
• Analyzed HR, MAP, seizure duration, recovery, and adverse events using random-effects models.

Main Results:

• Dexmedetomidine significantly attenuated the sympathetic response, reducing HR and MAP, particularly 0-4 minutes post-stimulus.
• Hemodynamic effects persisted up to 30 minutes without compromising seizure duration or recovery.
• Intermediate doses (0.25-0.5 µg/kg) showed the most consistent benefits.

Conclusions:

• Dexmedetomidine is a safe and effective adjunct for managing the autonomic surge during ECT.
• It does not negatively affect seizure quality or patient recovery.
• Further research is needed to standardize dosing and anesthetic protocols.